10.22.14
Sorin Group, a medical device company based in Milan, Italy, has earned the CE mark for its Memo 3D Rechord mitral valve annuloplasty ring. It is now available in Europe.
Memo 3D Rechord is a portfolio of solutions for all types of mitral valve disease, according to the company. It features a chordal guiding system intended to make artificial chordae tendineae replacement a routine and standardized procedure. The design includes a carbofilm coating and laser cut NiTi (nickel titanium) technology meant to provide physiologic performance.
“The Memo 3D Rechord is very easy to place, and the chordal system is indeed very useful, especially in minimally invasive surgery,” said Mattia Glauber, M.D., a cardiac surgeon who presented the first implantation of the ring at the European Association for Cardiothoracic Surgery annual meeting held in Milan in October. “I have tried it in both anterior and posterior prolapse cases, and it worked nicely in both situations without the need for further adjustments. Of course, we need to gain more experience to be able to guide surgeons to the correct indication, but this first experience was extremely positive.”
“In my opinion, this device has the potential to change the approach to mitral valve repair. We are facing a situation where we are resecting less and less while using more artificial chords; therefore, a system that helps to standardize artificial chord replacement is very timely,” Glauber added.
“Memo 3D Rechord is the latest result of our continuous effort to bring innovation to cardiac surgery teams. It represents a great opportunity to advance our presence in the mitral valve repair market,” said Michel Darnaud, president of the cardiac surgery business unit, Sorin Group. “It has been engineered to fulfill the growing demand for faster and more reproducible artificial chord replacement. We are committed to setting high standards in design and performance to support patients and cardiac surgeons in the management of mitral valve disease.”
Sorin Group’s focus is cardiovascular disease.
Memo 3D Rechord is a portfolio of solutions for all types of mitral valve disease, according to the company. It features a chordal guiding system intended to make artificial chordae tendineae replacement a routine and standardized procedure. The design includes a carbofilm coating and laser cut NiTi (nickel titanium) technology meant to provide physiologic performance.
“The Memo 3D Rechord is very easy to place, and the chordal system is indeed very useful, especially in minimally invasive surgery,” said Mattia Glauber, M.D., a cardiac surgeon who presented the first implantation of the ring at the European Association for Cardiothoracic Surgery annual meeting held in Milan in October. “I have tried it in both anterior and posterior prolapse cases, and it worked nicely in both situations without the need for further adjustments. Of course, we need to gain more experience to be able to guide surgeons to the correct indication, but this first experience was extremely positive.”
“In my opinion, this device has the potential to change the approach to mitral valve repair. We are facing a situation where we are resecting less and less while using more artificial chords; therefore, a system that helps to standardize artificial chord replacement is very timely,” Glauber added.
“Memo 3D Rechord is the latest result of our continuous effort to bring innovation to cardiac surgery teams. It represents a great opportunity to advance our presence in the mitral valve repair market,” said Michel Darnaud, president of the cardiac surgery business unit, Sorin Group. “It has been engineered to fulfill the growing demand for faster and more reproducible artificial chord replacement. We are committed to setting high standards in design and performance to support patients and cardiac surgeons in the management of mitral valve disease.”
Sorin Group’s focus is cardiovascular disease.